Valneva (NASDAQ:VALN) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and
UK MHRA revokes Valneva’s IXCHIQ chikungunya vaccine authorization over traveler benefit-risk review. Minimal financial impact expected.
Valneva stock drops after UK MHRA revokes Ixchiq chikungunya vaccine authorization over safety concerns. Read more here.
Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98% to $6.64.
Investing.com -- Valneva SE ADRs (NASDAQ:VALN) fell 6.5% in after-hours trading Wednesday after the UK revoked the marketing authorization for its IXCHIQ chikungunya vaccine following a benefit-risk review.
Lyon (France), October 07, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that, following a further benefit-risk assessment of IXCHIQ® for travelers by the United Kingdom’s (UK) Commission on Human Medicines (CHM), the UK marketing authorization for IXCHIQ® has been revoked by the Medicines and Healthcare products Regulatory Agency (MHRA). The decision was based on a review of previous safety data and was not associated with any newly identifi
Detailed price information for Valneva Se ADR (VALN-Q) from The Globe and Mail including charting and trades.
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies’ experimental Lyme disease vaccine candidate, and will now begin the official review. For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French […]
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans
Pfizer (NYSE:PFE) and Valneva announced that the European Medicines Agency has validated the Marketing Authorization Application for their Lyme disease vaccine candidate, PF-07307405. The validation starts the EMA regulatory assessment process for what could become a first in class Lyme disease vaccine for use in both North America and Europe. The application is supported by Phase 3 efficacy data, with the companies highlighting an unmet medical need in Lyme disease prevention. This move by...
This is the newest page. Registered accounts read further back.